

## Alexa Fluor<sup>®</sup> 700 anti-mouse CD45 Antibody

<b>Catalog# / Size</b>	103127 / 25 µg 103128 / 100 µg
<b>Clone</b>	30-F11
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T200, Ly-5, LCA
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Alexa Fluor <sup>®</sup> 700 under optimal conditions.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a> <a href="#">SB - Reported in the literature, not verified in house</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a>. The suggested use of this reagent is ≤ 0.25 µg per 10<sup>6</sup> cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.</p> <p>* Alexa Fluor<sup>®</sup> 700 has a maximum emission of 719 nm when it is excited at 633nm / 635nm. Prior to using Alexa Fluor<sup>®</sup> 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.</p> <p>Alexa Fluor<sup>®</sup> and Pacific Blue™ are trademarks of Life Technologies Corporation.</p> <p><a href="#">View full statement regarding label licenses</a></p>
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	<p>Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.</p> <p>Additional reported applications (for relevant formats) include: immunoprecipitation<sup>3</sup>, complement-dependent cytotoxicity<sup>1,5</sup>, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)<sup>4,6</sup>, Western blotting<sup>7</sup>, and spatial biology (IBEX)<sup>10,11</sup>. The Ultra-LEAF™ purified antibody (Endotoxin &lt; 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).</p>
<b>Additional Product Notes</b>	Iterative Bleaching Extended multi-plexity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent

antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

## Application References

(PubMed link indicates BioLegend citation)

1. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (FC, CMCD) [PubMed](#)
2. Haynes NM, *et al.* 2007. *J. Immunol.* 179:5099. (FC)
3. Ledbetter JA, *et al.* 1979. *Immunol. Rev.* 47:63. (IP)
4. Simon DI, *et al.* 2000. *J. Clin. Invest.* 105:293. (IHC)
5. Seaman WE. 1983. *J. Immunol.* 130:1713. (CMCD)
6. Cornet A, *et al.* 2001. *P. Natl. Acad. Sci. USA* 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. *J. Biol. Chem.* 273:30680. (WB) [PubMed](#)
8. Liu F, *et al.* 2012. *Blood.* 119:3295. [PubMed](#)
9. Pelletier AN, *et al.* 2012. *J. Immunol.* 188:5561. [PubMed](#)
10. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
11. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Stoupa A, *et al.* 2018. *EMBO Mol Med.* 10:. [PubMed](#)
2. Komuczki J, *et al.* 2019. *Immunity.* 50:1289. [PubMed](#)
3. Saha D *et al.* 2017. *Cancer cell.* 32(2):253-267 . [PubMed](#)
4. Tomida S, *et al.* 2019. *Sci Rep.* 9:10751. [PubMed](#)
5. Wong Fok Lung T, *et al.* 2020. *Nat Microbiol.* 141:5. [PubMed](#)
6. Gonalves S, *et al.* 2021. *Cell Reports.* 34(11):108860. [PubMed](#)
7. Ren Z, *et al.* 2021. *EMBO Molecular Medicine.* :e14059. [PubMed](#)
8. Trittel S, *et al.* 2019. *Sci Rep.* 9:16362. [PubMed](#)
9. Fu R, *et al.* 2020. *Sci Rep.* 10:1455. [PubMed](#)
10. Guzzi N *et al.* 2018. *Cell.* 173(5):1204-1216 . [PubMed](#)
11. Schloss MJ, *et al.* 2022. *Nat Immunol.* 23:605. [PubMed](#)
12. Ferrere G, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
13. Daskou M, *et al.* 2022. *PLoS Pathog.* 18:e1010160. [PubMed](#)
14. Jong RM, *et al.* 2022. *J Immunol.* 208:407. [PubMed](#)
15. Zhang R, *et al.* 2021. *Cell Mol Immunol.* 18:1222. [PubMed](#)
16. Xi H, *et al.* 2016. *J Exp Med.* 213: 189 - 207. [PubMed](#)
17. Hu X, *et al.* 2016. *Nat Commun.* 7:13095. [PubMed](#)
18. Merz SF, *et al.* 2019. *Nat Commun.* 10:2312. [PubMed](#)
19. Gimblet C *et al.* 2017. *Cell host & microbe.* 22(1):13-24 . [PubMed](#)
20. Putnam NE, *et al.* 2019. *PLoS Pathog.* 15:e1007744. [PubMed](#)
21. Chen J, *et al.* 2021. *Sci Adv.* 7:. [PubMed](#)
22. Ghosh S, *et al.* 2022. *APL Bioeng.* 6:036105. [PubMed](#)
23. Abou-Hamad J, *et al.* 2022. *iScience.* 25:105524. [PubMed](#)
24. Acharya N, *et al.* 2020. *Immunity.* 53(3):658-671.e6. [PubMed](#)
25. Katsura A, *et al.* 2017. *Mol Oncol.* 11:1241. [PubMed](#)
26. Amir M, *et al.* 2018. *Cell Rep.* 25:3733. [PubMed](#)
27. Haertel E, *et al.* 2018. *Eur J Immunol.* 48:1001. [PubMed](#)
28. Tordesillas L, *et al.* 2018. *Nat Commun.* 9:5238. [PubMed](#)
29. Zhang C, *et al.* 2022. *J Extracell Vesicles.* 11:e12209. [PubMed](#)
30. Ma C, *et al.* 2022. *Proc Natl Acad Sci U S A.* 119:. [PubMed](#)
31. Fujii Y, *et al.* 2022. *JBMR Plus.* 6:e10562. [PubMed](#)
32. Menzel L, *et al.* 2021. *Cell Rep.* 37:109878. [PubMed](#)
33. Evren E, *et al.* 2020. *Immunity.* 54(2):259-275.e7. [PubMed](#)
34. Schiller M, *et al.* 2021. *Immunity.* 54(5):1022-1036.e8. [PubMed](#)
35. Wang X, *et al.* 2020. *Signal Transduct Target Ther.* 5:35. [PubMed](#)
36. Egusquiza RJ, *et al.* 2020. *Environ Health Perspect.* 128:47011. [PubMed](#)
37. McDowell SAC, *et al.* 2021. *Nat Cancer.* 2:545. [PubMed](#)
38. Reyes RM, *et al.* 2021. *Oncoimmunology.* 10:2006529. [PubMed](#)
39. Lebratti T, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
40. Vackova J, *et al.* 2020. *Int J Mol Sci.* 21:00. [PubMed](#)
41. Yang R, *et al.* 2012. *J Immunol.* 189:2656. [PubMed](#)
42. Kienzl M, *et al.* 2020. *Oncoimmunology.* 9:1776059. [PubMed](#)
43. Cao W, *et al.* 2017. *Immunity.* 47:1182. [PubMed](#)
44. van Elsas MJ, *et al.* 2022. *Int J Mol Sci.* 23:. [PubMed](#)
45. Stutchfield B, *et al.* 2015. *Gastroenterology.* 149: 1896-1909.e14. [PubMed](#)
46. Doty DT, *et al.* 2020. *Int J Mol Sci.* 21:00. [PubMed](#)
47. Sun L, *et al.* 2020. *J Immunol.* 2177:204. [PubMed](#)
48. Magupalli VG, *et al.* 2020. *Science.* :369. [PubMed](#)
49. Li J, *et al.* 2020. *Cancer Discov.* . [PubMed](#)
50. Daubeuf F, *et al.* 2017. *Curr Protoc Mouse Biol.* 10.1002/cpmo.26. [PubMed](#)
51. Emgård J, *et al.* 2018. *Immunity.* 143:419. [PubMed](#)
52. Shan M *et al.* 2018. *Immunity.* 49(4):709-724 . [PubMed](#)
53. Koliaraki V *et al.* 2019. *Cell reports.* 26(3):536-545 . [PubMed](#)
54. Sophie Thiemann *et al.* 2017. *Cell host & microbe.* 21(6):682-694 . [PubMed](#)
55. Zhang D, *et al.* 2020. *Signal Transduct Target Ther.* 5:24. [PubMed](#)
56. Tanaka S, *et al.* 2012. *J Immunol.* 188:6145. [PubMed](#)
57. Wei JL, *et al.* 2021. *J Immunother Cancer.* 9: . [PubMed](#)
58. Fantauzzi MF, *et al.* 2021. *ERJ Open Res.* 7: . [PubMed](#)
59. Daubeuf F, *et al.* 2021. *Cells.* 10:. [PubMed](#)
60. An J, *et al.* 2022. *iScience.* 25:103570. [PubMed](#)
61. Chen ELY, *et al.* 2021. *Cell Rep.* 35:109227. [PubMed](#)

62. Menzel L, *et al.* 2022. STAR Protoc. 3:101267. [PubMed](#)
63. Abu El Maaty MA, *et al.* 2022. Sci Adv. 8:eabo2295. [PubMed](#)
64. Carozza JA, *et al.* 2020. Nat Cancer. 184:1. [PubMed](#)
65. Levi J, *et al.* 2020. J Nucl Med. . [PubMed](#)
66. Ruhland MK, *et al.* 2020. Cancer Cell. 37(6):786-799.e5. [PubMed](#)
67. Li J, *et al.* 2020. Cancer Immunol Res. 0.529166667. [PubMed](#)
68. Duque-Correa MA, *et al.* 2022. Nat Commun. 13:1725. [PubMed](#)
69. Muñoz NM, *et al.* 2022. Sci Rep. 12:14449. [PubMed](#)
70. He X, *et al.* 2021. Adv Sci (Weinh). 8:e2103023. [PubMed](#)
71. Tomlinson KL, *et al.* 2021. Nat Commun. 12:1399. [PubMed](#)
72. Benne N, *et al.* 2020. Adv Healthc Mater. 9:e2000043. [PubMed](#)
73. Prados A, *et al.* 2021. Nat Immunol. 22:510. [PubMed](#)
74. Coursey T, *et al.* 2016. Mucosal Immunol. 10.1038/mi.2016.83. [PubMed](#)
75. Bogie JF, *et al.* 2020. Ther Adv Chronic Dis. 11:2040622320947378. [PubMed](#)
76. Riquelme SA, *et al.* 2020. Cell Metabolism. 31(6):1091-1106.e6. [PubMed](#)
77. He Y, *et al.* 2021. Cell Metabolism. 33(5):988-1000.e7. [PubMed](#)
78. Noah AC, *et al.* 2020. J Appl Physiol (1985). 473:128. [PubMed](#)
79. Hossain DMS, *et al.* 2018. J Clin Invest. 128:644. [PubMed](#)
80. Grzelak A, *et al.* 2018. Int J Mol Sci. 19:. [PubMed](#)
81. Guérin MV, *et al.* 2019. Nat Commun. 10:4131. [PubMed](#)
82. Li J, *et al.* 2018. Immunity. 49:178. [PubMed](#)
83. Garcia LR, *et al.* 2021. Nat Commun. 12:3364. [PubMed](#)
84. Progzatky F, *et al.* 2021. Nature. 599:125. [PubMed](#)
85. Zhao F, *et al.* 2022. Nat Commun. 13:6117. [PubMed](#)
86. McFarland AP, *et al.* 2021. Immunity. 54(6):1320-1337.e4. [PubMed](#)
87. Abboud D, *et al.* 2015. Sci Rep. 5: 14746. [PubMed](#)
88. O'Connor T, *et al.* 2020. Cancer Cell. 36(3):250-267. [PubMed](#)
89. Yadava K *et al.* 2019. Elife. 8 pii: e44821. [PubMed](#)
90. Acker KP, *et al.* 2019. iScience. 19:281. [PubMed](#)
91. Schmid MC, *et al.* 2022. Nat Commun. 13:1768. [PubMed](#)
92. Chen X, *et al.* 2022. Front Immunol. 13:828319. [PubMed](#)
93. He X, *et al.* 2022. Cancer Immunol Res. 10:314. [PubMed](#)
94. Xiong H, *et al.* 2021. Theranostics. 11:1594. [PubMed](#)
95. Frank E, *et al.* 2016. Toxicol Pathol. 10.1177/0192623315620587. [PubMed](#)
96. Hiebert P *et al.* 2018. Developmental cell. 46(2):145-161 . [PubMed](#)
97. Sitaraman S, *et al.* 2019. Sci Rep. 9:12509. [PubMed](#)
98. Shannon JP, *et al.* 2021. STAR Protoc. 2:100790. [PubMed](#)
99. Park HB, *et al.* 2020. Nat Microbiol. 1319:5. [PubMed](#)
100. Shannon JP, *et al.* 2021. Immunity. 54(2):276-290.e5. [PubMed](#)
101. Kostadinova E, *et al.* 2016. Sci Rep. 6:30943. [PubMed](#)
102. Leyva-Castillo JM *et al.* 2019. Immunity. 50(5):1262-1275 . [PubMed](#)
103. Avraham S, *et al.* 2019. Oncogene. 38:3812. [PubMed](#)
104. Uderhardt S, *et al.* 2019. Cell. 177:541. [PubMed](#)
105. Cohen M *et al.* 2018. Cell. 175(4):1031-1044 . [PubMed](#)
106. Zhang HG, *et al.* 2022. Cell Res. .: [PubMed](#)
107. Zhai K, *et al.* 2021. Nat Cancer. 2:1136. [PubMed](#)
108. Puigdelloses M, *et al.* 2021. J Immunother Cancer. 9:. [PubMed](#)
109. Henrich IC, *et al.* 2021. Cancer Res. 81:2171. [PubMed](#)
110. Clark JT, *et al.* 2021. eLife. 10:00. [PubMed](#)
111. Nanou A, *et al.* 2021. Cell Reports. 35(8):109168. [PubMed](#)
112. Ahn D, *et al.* 2021. Cell Reports. 35(9):109196. [PubMed](#)
113. Koelwyn GJ, *et al.* 2020. Nat Med. 1452:26. [PubMed](#)
114. Philip E Boulais *et al.* 2018. Immunity. 49(4):627-639 . [PubMed](#)
115. Crauste F, *et al.* 2017. Cell Syst. 0.379166667. [PubMed](#)
116. Nair S, *et al.* 2021. JCI Insight. 6:. [PubMed](#)
117. Ma J, *et al.* 2021. J Transl Med. 19:477. [PubMed](#)
118. Artham S, *et al.* 2020. Am J Physiol Lung Cell Mol Physiol. L750:318. [PubMed](#)
119. Vacca F, *et al.* 2020. eLife. 9:e54017.. [PubMed](#)
120. Ji G, *et al.* 2019. Bone Joint J. 101-B:108. [PubMed](#)
121. Spangenberg E, *et al.* 2019. Nat Commun. 10:3758. [PubMed](#)
122. Stevenson ER, *et al.* 2022. J Pharmacol Exp Ther. 382:356. [PubMed](#)
123. Murray MP, *et al.* 2022. Cell Rep. 38:110209. [PubMed](#)
124. Dustin CM, *et al.* 2021. J Immunol. 206:2989. [PubMed](#)
125. Pizzurro GA, *et al.* 2021. Cancers (Basel). 13:. [PubMed](#)
126. Bollenbach M, *et al.* 2021. Molecules. 26:. [PubMed](#)
127. Grajchen E, *et al.* 2020. J Neuroinflammation. 0.863888889. [PubMed](#)
128. Dhar P, *et al.* 2021. Commun Biol. 4:905. [PubMed](#)
129. Abu El Maaty MA, *et al.* 2021. Sci Adv. 7: . [PubMed](#)
130. Zhang MS, *et al.* 2022. Nat Commun. 13:954. [PubMed](#)
131. Gicheva N, *et al.* 2016. Biochem Biophys Res Commun. 479:1-4. [PubMed](#)
132. Natale CA, *et al.* 2018. Elife. 7. [PubMed](#)
133. Ayturk UM, *et al.* 2020. J Bone Miner Res. 35:1981. [PubMed](#)
134. Chen Y, *et al.* 2022. Nat Commun. 13:4468. [PubMed](#)
135. He X, *et al.* 2021. J Immunother Cancer. 9:. [PubMed](#)
136. Xiao Y, *et al.* 2021. Cell. 184:6037. [PubMed](#)
137. Cambridge E, *et al.* 2017. Exp Hematol. 45:64-68.e5. [PubMed](#)
138. Zhang D, *et al.* 2020. Signal Transduct Target Ther. 5:24. [PubMed](#)
139. Nicolas-Boluda A, *et al.* 2021. eLife. 10:00. [PubMed](#)
140. Mathewson ND, *et al.* 2021. Cell. 184(5):1281-1298.e26. [PubMed](#)
141. Di Pilato M, *et al.* 2021. Cell. 184(17):4512-4530.e22. [PubMed](#)

142. Korin B, *et al.* 2020. *Sleep.* :43. [PubMed](#)
143. Van der Meer JM, *et al.* 2020. *Cancer Immunol Immunother.* . [PubMed](#)
144. Aguilar-Pimentel A, *et al.* 2017. *PLoS One.* 12(6):e0178563. [PubMed](#)
145. Bommareddy PK, *et al.* 2019. *J Biol Methods.* 6:2. [PubMed](#)
146. Hayashida E, *et al.* 2019. *J Neuroinflammation.* 0.789583333. [PubMed](#)
147. Schaftenaar FH, *et al.* 2019. *Sci Rep.* 9:17391. [PubMed](#)
148. Molgora M, *et al.* 2020. *Cell.* 182:886. [PubMed](#)
149. Zhang Z, *et al.* 2020. *Front Immunol.* 11:583276. [PubMed](#)
150. Jiang Y, *et al.* 2021. *Nat Commun.* 12:742. [PubMed](#)
151. Melhem NJ, *et al.* 2021. *Circulation.* 143:566. [PubMed](#)
152. Smith KJ, *et al.* 2022. *PLoS Biol.* 20:e3001554. [PubMed](#)
153. Hackstein CP, *et al.* 2022. *Nat Commun.* 13:7472. [PubMed](#)
154. Maulhardt HA, *et al.* 2020. *Invest New Drugs.* 1618:38. [PubMed](#)
155. Wang M, *et al.* 2021. *iScience.* 24(7):102766. [PubMed](#)
156. Guey B, *et al.* 2014. *Proc Natl Acad Sci U S A.* 111:17254. [PubMed](#)
157. Silva HM, *et al.* 2019. *J Exp Med.* 216:786. [PubMed](#)
158. Hartwig T *et al.* 2017. *Molecular cell.* 65(4):730-742 . [PubMed](#)
159. Litwinoff EMS, *et al.* 2017. *Obes Res Clin Pract.* 12:174. [PubMed](#)
160. White JP *et al.* 2018. *Cell.* 175(5):1198-1212 . [PubMed](#)
161. Dye BR, *et al.* 2020. *Biomaterials.* 234:119757. [PubMed](#)
162. Lee GR, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
163. Chetty A, *et al.* 2021. *Cell Host Microbe.* 29:579. [PubMed](#)
164. Maller O, *et al.* 2020. *Nat Mater.* 20:548. [PubMed](#)
165. Tian F, *et al.* 2016. *Nat Commun.* 7:13283. [PubMed](#)
166. Sen D, *et al.* 2016. *PLoS One.* 11:e0165064. [PubMed](#)
167. Peltzer N, *et al.* 2018. *Nature.* 557:112. [PubMed](#)
168. Miao Y *et al.* 2019. *Cell.* 177(5):1172-1186 . [PubMed](#)
169. O'Boyle C, *et al.* 2020. *Int J Stroke.* 0.746527778. [PubMed](#)
170. Pflügler S, *et al.* 2020. *Commun Biol.* 3:252. [PubMed](#)
171. Gangoso E, *et al.* 2021. *Cell.* 184:2454. [PubMed](#)
172. Pattabiraman G, *et al.* 2021. *Am J Physiol Renal Physiol.* . [PubMed](#)
173. Strait AA, *et al.* 2021. *Commun Biol.* 4:1005. [PubMed](#)
174. Trivedi S, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
175. Laczko D, *et al.* 2020. *Immunity.* 53:724. [PubMed](#)
176. Harvey RE *et al.* 2017. *Endocrinology.* 158(7):2179-2189 . [PubMed](#)
177. Wolf Y, *et al.* 2019. *Cell.* 179:219. [PubMed](#)
178. Riopel M, *et al.* 2019. *Mol Metab.* 20:89. [PubMed](#)
179. Rossi G, *et al.* 2022. *Sci Rep.* 12:13380. [PubMed](#)
180. Hohsfield LA, *et al.* 2021. *Elife.* 10:. [PubMed](#)

**RRID** AB\_493714 (BioLegend Cat. No. 103127)  
 AB\_493715 (BioLegend Cat. No. 103128)

## Antigen Details

---

<b>Structure</b>	Protein tyrosine phosphatase (PTP) family, 180-240 kD
<b>Distribution</b>	All hematopoietic cells except mature erythrocytes and platelets
<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
<b>Cell Type</b>	B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li> <li>2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.</li> <li>3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.</li> <li>4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.</li> </ol>
<b>Gene ID</b>	<a href="#">19264</a>

## Related Protocols


---

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

APC anti-mouse CD45, Biotin anti-mouse CD45, FITC anti-mouse CD45, PE anti-mouse CD45, PE/Cyanine5 anti-mouse CD45, Purified anti-mouse CD45, PE/Cyanine7 anti-mouse CD45, APC/Cyanine7 anti-mouse CD45, Alexa Fluor® 488 anti-mouse CD45, Alexa Fluor® 647 anti-mouse CD45, Pacific Blue™ anti-mouse CD45, Alexa Fluor® 700 anti-mouse CD45, PerCP/Cyanine5.5 anti-mouse CD45, PerCP anti-mouse CD45, Alexa Fluor® 594 anti-mouse CD45, Brilliant Violet 421™ anti-mouse CD45, Brilliant Violet 570™ anti-mouse CD45, Brilliant Violet 510™ anti-mouse CD45, Brilliant Violet 605™ anti-mouse CD45, Purified anti-mouse CD45 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45, Brilliant Violet 711™ anti-mouse CD45, Brilliant Violet 785™ anti-mouse CD45, Brilliant Violet 650™ anti-mouse CD45, APC/Fire™ 750 anti-mouse CD45, Brilliant Violet 750™ anti-mouse CD45, TotalSeq™-A0096 anti-mouse CD45, TotalSeq™-B0096 anti-mouse CD45, Ultra-LEAF™ Purified anti-mouse CD45, Spark Blue™ 550 anti-mouse CD45, Spark NIR™ 685 anti-mouse CD45, TotalSeq™-C0096 anti-mouse CD45, Spark YG™ 570 anti-mouse CD45, PE/Fire™ 640 anti-mouse CD45, APC/Fire™ 810 anti-mouse CD45, PE/Fire™ 700 anti-mouse CD45, Spark Violet™ 538 anti-mouse CD45, Spark YG™ 593 anti-mouse CD45, Spark Blue™ 574 anti-mouse CD45 Antibody

## Product Data



C57BL/6 mouse splenocytes stained with 30-F11 Alexa Fluor® 700



Confocal image of C57BL/6 mouse liver sample acquired using the IBEX method of highly multiplexed antibody-based imaging: E-Cadherin (red) in Cycle 1 and CD45 (cyan) in Cycle 3. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587